CochLear (OTCMKTS:CHEOY) Reaches New 1-Year Low - What's Next?

Key Points

• CochLear hit a new 52‑week low — the ADR traded as low as $34.80 and last at $36.44 versus a prior close of $59.77, a decline of about 39.0% on volume of 117,462 shares.
• Analyst sentiment remains mildly positive — the stock has an average rating of "Buy" (two Strong Buy, one Buy, two Hold), with recent reports including RBC upgrading to "moderate buy" and Zacks upgrading to "hold".
• Technicals show sustained weakness — the 50‑day SMA is $63.20 and the 200‑day SMA is $81.08, both substantially above the current price, indicating downward momentum.

CochLear Ltd. Unsponsored ADR (OTCMKTS:CHEOY - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $34.80 and last traded at $36.44, with a volume of 117462 shares traded. The stock had previously closed at $59.77.

Analyst Upgrades and Downgrades

CHEOY has been the subject of several recent analyst reports. Zacks Research upgraded CochLear to a "hold" rating in a report on Friday, April 17th. Royal Bank Of Canada upgraded CochLear from a "hold" rating to a "moderate buy" rating in a report on Monday, January 19th. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy".

CochLear Stock Down 39.0%

The firm has a fifty day simple moving average of $63.20 and a 200-day simple moving average of $81.08.

About CochLear

Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.